# Grattan Woodson M.D., P.C.

**Optimal Health and Wellness** | **Atlanta Research Center** | **Osteoporosis Center of Atlanta**

## GRATTAN CROWE WOODSON, III, M.D., F.A.C.P
## CURRICULUM VITAE

**DATE: January 2017**


**Office Address**
1418 Dresden Dr., Suite 225
Atlanta, Georgia 30319

**Office Telephone Numbers**
Voice: 404.574.2373
Facsimile: 404.298.5577

**Web Sites**
www.JointRegen.net
www.ARCenter.net
www.OsteoTest.com
www.DrGWoodson.com


## ACADEMIC AND PROFESSIONAL BACKGROUND

Northside High School, Atlanta, Ga. 1970

Oglethorpe University, Atlanta, Ga. BS 1976

Research Fellowship, Anatomic Pathology, Medical College of Georgia 1978

Medical College of Georgia, Augusta, Ga. M.D. 1980

Categorical Internship and Residency in Internal Medicine MI Bassett Hospital, Cooperstown, NY 1980-83

Clinical Fellow in Medicine, Columbia University College of Physicians and Surgeons, 1980-83

Senior Associate, Department of Medicine, Emory University School of Medicine, 1983-86

Clinical Instructor of Medicine, Emory University School of Medicine, 1986 - 2009

Attending Physician in Internal Medicine, Atlanta Center for Medicine, 1986 - 1997

Medical Director, Osteoporosis Center of Atlanta, 1988 - present

Medical Director, Atlanta Research Center 1989 - present

Attending Physician, Grattan Woodson M.D, PC 1997 – present

# PROFESSIONAL ORGANIZATIONS

Certified by the American Board of Internal Medicine 1983

Fellow of the American College of Physicians 1993

Member of the American Society for Bone and Mineral Research since 1986

Member of the American Society of Internal Medicine 1988

President of the Georgia Chapter of the National Osteoporosis Foundation, 1987-91

Member of the Scientific Advisory Board of the National Osteoporosis Foundation Washington, DC 1989-1995

Education Committee, Scientific Advisory Board of the National Osteoporosis Foundation 1990-1995

Member of the Clinical Society for Bone Densitometry 1993, Certified Bone Densitometrist since 2006

Member of the Southeastern Regional Scientific Advisory Board of the Better Bones Alliance, Proctor and Gamble Pharmaceuticals and Aventis, 1998 - 2003

Member of the National Internal Medicine Advisory Board, Eli Lilly and Company 2001-2005

Member of the US Bazedoxifene Steering Committee, Wyeth Research, 2002 – 2005

## HOSPITAL AFFILIATIONS

Emory University Hospital 1983-1986
Grady Memorial Hospital 1983-1986
DeKalb Medical Center, Decatur, Georgia since 1986-present

## CONTRACT RESEARCH EXPERIENCE

### OSTEOARTHRITIS

1998-1999
Principal Investigator
Sponsor: Merck Human Health
Protocol: A randomized, placebo and active comparator-controlled, parallel group, double blind study to compare the efficacy and safety of MK-0966 tablets vs. nabumetone tablets in patients with osteoarthritis of the knee.
Drug: rofecoxib (Vioxx®) and nabumetone (Relafen®)

1999-2000
Principal Investigator
Protocol: Clinical Protocol for the Multicenter, Double-bind, Parallel Group Study Comparing the Effects on Renal Function and the Incidence of Gastrointestinal Ulcer Associated with Valdecoxib 20 mg and 40 mg with that of Naproxen 500 mg bid in Patients with Osteoarthritis or Rheumatoid Arthritis.
Sponsor: Searle - Pfizer
Drug: valdecoxib (Bextra®) and naproxen sodium (Naprosyn®)

1999 – 2000
Principal Investigator
Sponsor: Bayer
Protocol: A multi-center, double blind, placebo controlled, group comparison study to investigate the efficacy, tolerability and safety of BAY 12,9566 as compared to placebo, in the treatment of patients with mild to moderate osteoarthritis of the knee, over 3 years, #100011
Drug: BAY 12, 9566 (Metaloprotease inhibitor)

2000-2001
Principal Investigator
Protocol: A randomized placebo-controlled, parallel group, double blind study to evaluate the safety and efficacy of rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg n patients with osteoarthritis of the knee or hip.
Sponsor: Merck Research Laboratories
Drug: rofenoxib (Vioxx®) and celecoxib (Celebrex®)

1998-1999
Principal Investigator
Sponsor: Merck Human Health
Protocol: A randomized, placebo and active comparator-controlled, parallel group, double blind study to compare the efficacy and safety of MK-0966 tablets vs. nabumetone tablets in patients with osteoarthritis of the knee.
Drug: rofecoxib (Vioxx®) and nabumetone (Relafen®)

1999-2000
Principal Investigator
Protocol: Clinical Protocol for the Multicenter, Double-bind, Parallel Group Study Comparing the Effects on Renal Function and the Incidence of Gastrointestinal Ulcer Associated with Valdecoxib 20 mg and 40 mg with that of Naproxen 500 mg bid in Patients with Osteoarthritis or Rheumatoid Arthritis.
Sponsor: Searle - Pfizer
Drug: valdecoxib (Bextra®) and naproxen sodium (Naprosyn®)

1999 – 2000
Principal Investigator
Sponsor: Bayer
Protocol: A multi-center, double blind, placebo controlled, group comparison study to investigate the efficacy, tolerability and safety of BAY 12,9566 as compared to placebo, in the treatment of patients with mild to moderate osteoarthritis of the knee, over 3 years, #100011
Drug: BAY 12, 9566 (Metaloprotease inhibitor)

2000-2001
Principal Investigator
Protocol: A randomized placebo-controlled, parallel group, double blind study to evaluate the safety and efficacy of rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg n patients with osteoarthritis of the knee or hip.
Sponsor: Merck Research Laboratories
Drug: rofenoxib (Vioxx®) and celecoxib (Celebrex®)

2003-2004
Principal Investigator

Sponsor: GSK
A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of oral GW406381 1mg, 5mg, 10mg, 25mg and 50mg administered once daily, in adults with Osteoarthritis of the knee.
Drug: GW406381

2005-2006
Principal Investigator
Sponsor: Pfizer
Protocol: Double-Blind, Parallel-Group, Randomized, Study Of The Efficacy And Safety Of Continuous Use Of Celecoxib Vs The "Usual Use" Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require An Anti-Inflammatory Medication For Control Of Their Pain
Drug: Celecoxib (Celebrex®)

2005-2006
Principal Investigator
Protocol: A 13-week, Double-Blind, Parallel, Randomized, Placebo- and Naproxen-controlled HCT 3012-X-301 Efficacy and Safety Study
Sponsor: NicOX SA
Drug: HCT 3012 and naproxen sodium (Naprosyn®)

2006-2007
Principal Investigator
Protocol: A Parallel, Randomized, Open-Label, Multicenter, 52-week Follow-up Safety Study of HCT 3012 (375 mg bid and 750 mg bid) in Subjects with Osteoarthritis of the Knee.
Sponsor: NicOX SA
Drug: HCT 3012

2007-2008
Principal Investigator
Protocol: BUP 3025: A Multi-center, Randomized, Double-blind, Placebo-controlled Study with an Open-label Run-in to Assess the Efficacy, Tolerability, and Safety of BTDS 10 or BTDS 20 Compared to Placebo in Opioid-naïve Subjects with Moderate to Severe, Chronic Pain due to Osteoarthritis of the Knee
Sponsor: Purdue Pharma
Drug: Buprenorphine

# MUSCULOSKELETAL PAIN

1997-1999
Principal Investigator
Sponsor: Purdue Pharma
Protocol: Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 12.5, 25. and 50ug/hr Applied every Seven Days for Sixty Days vs 5mg Oxycodone/325 mg acetomenophen Tablets q6h PRN vs Placebo in Patients with Chronic Back Pain, BP96-102
Drug: Buprenorphine

1997-1999
Principal Investigator
Sponsor: Purdue Pharma
Protocol: A Long-Term, Open-Label, Clinical Use Safety Study of Buprenorphine TDS (Transdermal Delivery System) 12.5, 25, and 50ug/hr Applied Every 72 hours for the Management of Ongoing Pain Syndromes, BP96-0103
Drug: Buprenorphine and Oxycodone/Acetomentophen (Percocet®)

1998-1999
Principal Investigator
Sponsor: Purdue Pharma
Protocol: A Comparative Study of Buprenorphine TDS, Oxycodone/Acetomentophen Tablets QID and Placebo in Patients with Chronic Back Pain, BP96-0604
Drug: Buprenorphine and Oxycodone/Acetomentophen (Percocet®)

2006-2007
Principal Investigator
Sponsor: Pfizer
Protocol: A six-week double blind, randomized, multicenter comparison study of the analgesic effectiveness of Celecoxib 200 mg BID compared to Tramadol Hydrochloride 50 mg QID in subjects with chronic low back pain.
Drug: Celecoxib (Celebrx®) and tramidol (Ultram®)

2007-2008
Principal Investigator
Sponsor: Wyeth
Protocol: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy, Safety And Tolerability Study Of 4 Fixed Oral Doses Of Dvs Sr In Adult Outpatients With Fibromyalgia Syndrome (3151A4-327-US)
Drug: Desvelafaxine Succinate (DVS SR)

2007-2010
Principal Investigator

Sponsor: Forest Labs
Protocol: A Phase III Pivotal, Multi-center, Double Blind, Randomized, Placebo-Controlled Mono-therapy Study of Milnacipran for Treatment of Fibromyalgia
Drug: Milnacipran

2008-2009
Principal Investigator
Sponsor: Wyeth Research
Protocol: A Multicenter, Randomized Double-Blind, Placebo-Controlled Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome. (3151A4-2003-US) Phase 2
Drug: Desvelafaxine Succinate (DVS SR) and pregabalin (Lyirca®)

2017-present
Principal Investigator
Sponsor: Grunenthal
Protocol: Bone biopsy sub study: Open-label safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
Drug: Neridronic acid

# OSTEOPOROSIS STUDIES

1985-1990
Principal Investigator
Sponsor: Norwich Eaton Pharmaceuticals (Division of Proctor and Gamble)
Protocol: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis PMOII
Drug: Etidronate disodium (Didronel®)

1990-1998
Principal Investigator
Sponsor: Sandoz Pharmaceutical
Protocol: A multi-centered, double-blind, placebo-controlled study to investigate the efficacy of salmon calcitonin nasal spray in the prevention of osteoporotic vertebral fractures, Miacalcin 320
Drug: Salmon calcitonin nasal spray (Miacalcin®)

1992-1997
Principal Investigator
Sponsor: Sanofi Winthrope
Protocol: A phase III study of intermittent cyclical tiludronate in the treatment of established post-menopausal osteoporosis, Tiludronate 004
Drug: Tiludronate (Skelid®)

1992-1996

Principal Investigator
Sponsor: Sanofi Winthrope
Protocol: A phase III study of intermittent cyclical tiludronate in the treatment of post-menopausal women with low bone mineral mass and no vertebral fractures, Tiludronate 0055
Drug: Tiludronate (Skelid®)

1993-1999
Principal Investigator
Sponsor: Proctor and Gamble Pharmaceuticals
Protocol: A multicenter, randomized, double-blind, placebo-controlled parallel group study to determine the efficacy and safety of risedronate in the treatment of osteoporosis in elderly women, RHN 9193
Drug: Risedronate (Actonel®)

1993-1995
Principal Investigator
Sponsor: Proctor and Gamble Pharmaceuticals
Protocol: A randomized, double-blind, placebo-controlled, multicenter, parallel group study to determine the efficacy and safety of risedronate in the treatment of postmenopausal osteopenic women, RON 9393
Drug: Risedronate (Actonel®)

1995-1998
Principal Investigator
Sponsor: Merck Human Health
Protocol: A triple-blind, randomized, placebo-controlled, parallel-group multicenter study to evaluate the safety, tolerability and effect on bone mineral density of 10mg of alendronate sodium for the treatment of postmenopausal osteoporosis in elderly female long term care facility residents, FOS351
Drug: Alendronate Sodium (Fosamax®)

1996-2000
Principal Investigator
Sponsor: Roche
Protocol: Multi-center, double-blind, placebo-controlled, randomized study on the efficacy and safety of ibandronate during 3 years' treatment in patients with postmenopausal osteoporosis and vertebral fractures using a continuous oral (2.5 mg daily) and an intermittent oral (20 mg every 2$^{nd}$ day for 24 days every 3 months) dosing regimen, MF4411
Drug: Ibandronate (Boniva®)

1997-1999
Principal Investigator
Sponsor: Merck Human Health

Protocol: A triple-blind, randomized, placebo-controlled multicenter study to compare efficacy of oral alendronate sodium to intranasal calcitonin-salmon for treatment of postmenopausal osteoporosis (IN-FOCAS), FOS417
Drug: Alendronate Sodium (Fosamax®)

1998-2000
Principal Investigator
Sponsor: Pfizer
Protocol: Safety and efficacy of droloxifene for preventing bone loss in normal, early postmenopausal women, 174-113
Drug: droloxifene, raloxifene (Evista®)

1998-2000
Principal Investigator
Sponsor: Novartis
Protocol: A Double-Blind, Placebo Controlled Safety and Efficacy Trial with Transdermal Zolendronate (CGP 42446) in the Treatment of Postmenopausal Osteoporosis, 18
Drug: Zolendronate (Reclast®)

1998-1999
Principal Investigator
Sponsor: Berlex
Protocol: A mulitcenter, double-blind, randomized, placebo controlled, study to evaluate the safety and efficacy of two doses of estradiol given by continuous transdermal administration in prevention of osteoporosis in postmenopausal women, 96041-B
Drug: Estradiol (Climara®)

1999-2000
Principal Investigator
Sponsor: Merck
Protocol: A double blind randomized placebo-controlled, multi-center study to evaluate upper gastrointestinal tolerability upon rechallange in postmenopausal women with osteoporosis who previously discontinued alendronate due to upper gastrointestinal symptoms.
Drug: alendronate (Fosamax®)

2001-2005
Principal Investigator
Sponsor: Wyeth Research
Protocol: A Multicenter, Double Blind, Randomized, Placebo, and Raloxifene-Controlled Study to Assess Safety and Efficacy of TSE-424 in the Prevention of Postmenopausal Osteoporosis, W300
Drug: Bazedoxifene acetate and raloxifene (Evista®)

2001-2005
Principal Investigator
Sponsor: Wyeth Research
Protocol: Fracture Incidence Reduction and Safety of TSE-424 (Bazedoxifene Acetate) Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women, W301
Drug: Bazedoxifene Acetate and raloxifene (Evista®)

2001-2004
Principal Investigator
Sponsor: Eli Lilly and Company
Protocol: Protocol Title: Comparison of Raloxifene to Alendronate in Postmenopausal Women with Osteoporosis (H3S-US-GGKO) EVA
Drug: Raloxifene (Evista®) and alendronate (Fosamax®)

2002-2005
Principal Investigator
Sponsor: Amgen
Protocol: A Randomized, Double-Blind, Placebo-controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety, and Tolerability of AMG 162 in the Treatment of Postmenopausal Women with Low Bone Mineral Density.
Drug: AMG 162 (denosamab) and alendronate (Fosamax®)

2002-2005
Principal Investigator
Sponsor: Novartis
Protocol: Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture.
Drug: Zoledronic Acid (Reclast®)

2003-2009
Principal Investigator
Sponsor: Eli Lilly and Company
Protocol: Forteo Observational Study, DANCE Study
Drug: Teraparatide (Forteo®)

2004-2006
Principal Investigator
Sponsor: Aventis Protocol: Open-label study to determine how prior therapy with Alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teraparatide, OPTIMIZE Study.
Drug: Teraparatide (Forteo®)

2004-2007
Principal Investigator

Sponsor: Proctor and Gamble Pharmaceuticals
Protocol: Bone Histomorphometry, Microarchitecture and Matrix Structure in Patients Receiving Long-term Alendronate or Risedronate
Drug: Risedronate (Actonel®) and alendronate (Fosamax®)

2004-2009
Principal Investigator
Sponsor: Eli Lilly and Company
Protocol: Effects of Arzoxifene on Vertebral Fracture Incidence and of Invasive Breast Cancer Incidence in Post Menopausal Women with Osteoporosis or Low Bone Density (GJAD)
Drug: Arzoxifene

2002-2005
Principal Investigator
Sponsor: Amgen
Protocol: A Randomized, Double blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women with Low Bone Mineral Density
Drug: Denosamab

2004-2005
Principal Investigator
Sponsor: Roche
Protocol: A prospective, open-label, multi-center, two-part study to investigate patient satisfaction with monthly dosed ibandronate therapy in women with postmenopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate
Drug: Ibandronate (Boniva®)

2004-2006
Principal Investigator
Sponsor: Roche
Protocol: A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis.
Drug: Ibandronate (Boniva®)

2005-2007
Principal Investigator
Sponsor: Amgen
Protocol: A Randomized, Double-Blind Study Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis (AMG 162 20040132)
Drug: Denosamab

2005-2008

Principal Investigator
Sponsor: Wyeth Research
Protocol: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy, and Safety study of Bazedoxifene/Conjugated Estrogens Combinations for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women (3115A1-304-WW)
Drug: Bazedoxifene and CCE (Premarin®)

2006-present
Principal Investigator
Sponsor: Amgen
Protocol: An Open-Label, Single-Arm Extension Study to Evaluate the Longer-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density (20050233)
Drug: Denosumab

2006-2008
Principal Investigator
Sponsor: GSK
Protocol: A parallel, placebo-controlled, randomized (2:1) double-blind study of one year duration to assess the effect of oral Ibandronate 150mg given once monthly verses placebo on lumbar spine bone mineral density in men with osteoporosis. (BON105960)
Phase 3
Drug: Ibandronate (Boniva®)

2006-2016
Principal Investigator
Sponsor: Merck
Protocol: A Phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of MK-0822 to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium.
Drug: MK-0822 (Cat-K inhibitor)

2006-2011
Principal Investigator
Sponsor: Lilly
Protocol Addendum B3D-MC-GHCY(1) The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures
Drug: Teraparatide (Forteo®)

2007-2008
Principal Investigator
Sponsor: GSK

Protocol: A Dose-Range Finding Study of SB-751689 in Post-Menopausal Women with Osteoporosis (CR9108963)
Drug: SB-751689 (Calcium receptor inhibitor)

2008-2009
Principal Investigator
Sponsor: Lilly
Protocol: Community Experience of Subjects with Osteoporosis Using the Forteo B Pen to Self-Administer Once-Daily Teriparatide Therapy (B3D-MC-GHDF)
Drug: Teraparatide (Forteo®) pen system

2009-2011
Principal Investigator
Sponsor: Lilly
Protocol: Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ)
Drug: Teraparatide (Forteo®) and Zoledronic Acid (Reclast®)

2011-2013
Principal Investigator
Sponsor: Radius Health
Protocol: A randomized, double-blind, placebo-controlled, comparator phase 3 multicenter study to evaluate the safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk for fracture.
Drug: Forteo, BA058 (PTHrp)

2017-present
Principal Investigator
Sponsor: Pfenex Inc.
Protocol: PF708-301 A Randomized Study Comparing the Effects of PF708 and Forteo in Patients with Osteoporosis
Drug: PF708: Teraparatide Product

# WOMEN'S HEALTH

1998-2000
Principal Investigator
Sponsor: Parke Davis
Protocol: A Randomized, Double-Blind, Active - and Placebo Controlled, Parallel Group, Multicenter Study Assessing the Safety and Protective Effect on the Endometrium of 4 Dosage Combinations of Norethindrone Acetate Plus Ethinyl Estradiol, 376-401
Drugs: Ethinyl Estradiol and Norethindrone (FemHrt®)

1999-2001
Principal Investigator
Sponsor: Parke Davis
Protocol: A 12-week, randomized, partially-blinded, active and placebo controlled, parallel group, multi-center study assessing the effect of norethendrone acetate plus ethinyl estradiol on endothelial dysfunction in postmenopausal women.
Drug: norethendrone, ethinyl estradiol, (FemHrt®) raloxifene (Evista®)

1999- 2001
Sub-investigator
Sponsor: Park Davis – Pfizer
Protocol: A 20-week open-label assessment of the safety and efficacy profile of atorvastatin when used to optimally control dyslipidemia in postmenopausal patents.
Acronym: DUET (Atrovastatin Drug Utilization and Experience Trial)
Drug: atorvastatin (Lipitor®)

1999- 2002
Principal Investigator
Sponsor: Parke Davis – Pfizer
Protocol: Beyond endorsed lipid lowering with EBCT scanning, BELLES
Drug: atorvastatin (Lipitor®) and pravastatin (Pravacol®)

2002-2005
Principal Investigator
Sponsor: Wyeth Research
Protocol: A Double-Blind, Randomized, Placebo and Active Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations Postmenopausal Women, (W303) Phase 3
Drug: Bazedoxifene Acetate and CCE (Premarin®) and raloxifene (Evista®)

2008-2009
Principal Investigator
Sponsor: Wyeth Research
Protocol: A Double-Blind, Randomized, Placebo-Controlled Study Assessing the Safety and Efficacy of DVS SR for the Treatment of Vasomotor Symptoms Associated with Menopause. (3151A2-3353-NA) Phase 3
Drug: Desvelafaxine Succinate (DVS SR)

2008-2009
Principal Investigator
Sponsor: QuatRx Pharmaceuticals
Protocol: Efficacy And Safety Of Ospemifene In The Treatment Of Moderate To Severe Vaginal Dryness And Vaginal Pain Associated With Sexual Activity, Symptoms Of Vulvar And Vaginal Atrophy (Vva), Associated With Menopause: A 12-Week,

Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study Comparing Oral Ospemifene 60 Mg Daily Dose With Placebo In Postmenopausal Women
Drug: Ospemifene

# PUBLICATIONS

## PEER REVIEWED JOURNAL ARTICLES

D. Hewitt, G. Woodson, L. L. Vacca A comparison of methods to localize peroxidase activity in erythrocytes and immunoperoxidase procedures. GA J Science, 1978; 3:101.

L. L. Vacca, D. Hewitt, G. Woodson, A comparison of methods using diaminobenzidine (DAB) to localize peroxidase in erythrocytes, neutrophils, and peroxidase-antiperoxidase complex. Stain Tech, 1978; 53:331-336.

G. Woodson, Coherence therapy with phosphate and etidronate for osteoporosis: preliminary results. in Osteoporosis 1987, Proceedings of the Second International Symposium on Osteoporosis Aalborg, Denmark pp. 1188-1189

N. B. Watts, G. Woodson, S. O'Neal, B.D. Catherwood Serum bone Gamma-carboxyglutamate- containing protein (BGP) declines with time after menopause but does not correlate with age. Abstract, Clinical Research, 1989; 37.

G. Woodson, Coherence therapy increases bone mass. Abstract, J Bone Min Res 1989: Supp 1.

N. B. Watts, S. T. Harris, H. K. Genant, R. D. Wasnich, P. D. Miller, R. D. Jackson, A. A. Licata, P. D. Ross, G. C. Woodson, M. J. Yanover, W. J. Mysiw, L. Kohse, M. B. Rao, P. Steiger, B. Richmond, C. H. Chestnut, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Eng J Med 1990; 323; 73-79.

G. Woodson, Etidronate combined with estrogen increases bone mass in osteopenia and osteoporosis. in Osteoporosis 1990, Proceedings of the third International Symposium on Osteoporosis Copenhagen, Denmark 14-20 October 1990 Eds Claus Christiansen and Kirsten Overgaard, pp 1476-1478.

S. M. Ott, G. C. Woodson, W. E. Huffer, Bone histomorphometric changes in women with postmenopausal osteoporosis treated with etidronate. in Osteoporosis 1990, Proceedings of the Third International Symposium on Osteoporosis Copenhagen, Denmark 14-20 October 1990 Eds Claus Christiansen and Kirsten Overgaard, pp 1318-1322.

G. Woodson, Carlson LM, Treating osteoporosis: the etidronate option. Senior Patient 1991;3:8-15.

S.M. Ott, G. C. Woodson, W.E. Hufer, P.D. Miller, N.B. Watts, Effects of etidronate and phosphate on bone histomorphology in women with postmenopausal osteoporosis. Abstract # 561, J Bone Min Res August 1991 (supp 1) pp s224.

G. Woodson, Three effective treatments for osteoporosis. Abstract presented at the Adult Bone and Mineral Working Group of the ASBMR, Tampa Sept 1993, J Bone Min Res 1993;s403.

Susan M. Ott, Grattan C. Woodson, William E. Huffer, Paul D. Miller, Nelson B. Watts, Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;78:968-972.

Woodson, G., Phosphate depletion, osteomalacia, and aluminum intoxication due to antacid use in a patient with normal renal function. Oral presentation at the Adult Bone and Mineral Group of the ASBMR, Baltimore, MD September 1995. J Bone Min Res 1995:(supp 1):

Woodson, G., Adequate screening for axial osteoporosis with densitometry requires measurement of the hip and spine. Poster presentation at the ASBMR, Baltimore, MD September 1995. J Bone Min Res 1995;(supp 1):

M McClung, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller, E Pavlov, S Silverman, G Woodson, K Kalkner, P Bekker,. Risedronate treatment of postmenopausal women with low bone mass: Preliminary Data. Osteoporosis Int 1996; (suppl 1):PTu 700

Woodson, G C.,. An effectiveness study of etidronate therapy with and without estrogen. J Bone Min Res 1996;(supp 1):M651

P Beeker, M McClung, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller, E Pavlov, S Silverman, GC Woodson, K Kalkner, D Axelrod,. Risedronate is effective in increasing BMD in both early and late postmenopausal women with low bone mass. J Bone Min Res 1997;(suppl 1): S474

McClung, M, W Benson, M Bolognese, S Bonnick, M Ettinger, S Harris, H Heath, R Lang , P Miller, E Pavlov, S Silverman, GC Woodson, K Kalkner, P Bekker, D Axelrod,. Risedronate increases BMD at the hip and spine in postmenopausal women with low bone mass. J Bone Min Res 1997;(suppl 1): P269

Woodson, G C., The diagnosis of osteoporosis using the NHANES II Vs the Hologic normative data for the femoral neck., J Bone Min Res 1997;(suppl 1): S531

Woodson, G C., The supine lateral site is more sensitive for the diagnosis of osteoporosis than other axial DXA sites. J Bone Min Res 1997;(suppl 1): F614

Woodson, G C., An interesting case of osteomalacia due to antacid use associated with stainable bone aluminum in a patient with normal renal function. Bone 1998; 22:6;695-985.

Silverman S, Genant HK, Kiel DP, Maricic MJ, Peacock M, Woodson GC., Salmon-Calcitonin nasal spray prevents fractures in established osteoporosis. Additional interim fracture analysis of the "PROOF" study. 1998 Bone; 23(suppl 5)

Chestnut C, Maricic MJ, Silverman S, Woodson GC., Are bone mineral density and biomarkers good predictors of efficacy for prevention of osteoporotic fractures? – Salmon-calcitonin nasal spray and alendronate. 1998 Bone; 23(suppl 5)

Woodson G C., DXA T-score Concordance and Discordance between the PA Spine and the Total Hip Sites. (Oral presentation ASBMR 10-1-99, St Louis, MO) 1999, JBMR 14;suppl 1:#1027, S139

Rosen C J, Bonnick SL, Miller PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ, Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal spray calcitonin (effect on bone markers). 1999, JBMR 14;suppl 1:# SA 364, S399.

Rosen C J, Bonnick SL, Miller PD, McClung MR, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ, Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton, ME., ., Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal spray calcitonin (effect on BMD) 1999, JBMR 14;suppl 1:# S365, S400.

Fogelman I, Moreland L, Woodson GC, Mellstrom D, Boling E, Riskin W, Strauss D, Stevens K, Manhart M., Gastrointestinal side effects and endoscopic findinings similar between risedronate and placebo-treated patients. 2000 Osteoprosis Int (Suppl 2)1179;459

Woodson G C., Once Weekly Risedronate Therapy. 2000, Osteoporosis Int (suppl 2) s204, 550

Hooper M, Hanley D, Eastell R, Boling B, Ribot C, Woodson GC, Barton I., Sustained Effect of Risedronate in the Prevention of the First Vertebral Fracture in Women. 2000, J Bone Min Res (suppl 1) SU400, s428

Josse R, Fogelman I, Woodson GC, Boling E, Stevens K,. Gastrointestinal side effects and endoscopic findings similar between risedronate and placebo treated patients. 2000, Presented at the Endocrine Society Meeting, Toronto, CA on 6-12-2000

Woodson, G C., T-score concordance and discordance between the hip and spine measurement sites. J. Clinical Densitometry, 2000;3:319-324.

Miller P, Woodson G C, Licata AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates J, Melton ME, Pamisano JJ,. Rechallange of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. 2000, Clin Ther 22;1433-1422.

Woodson G C Risk Factors for Osteoporosis in Postmenopausal African American Women 2003, J Bone and Mineral Res., Supp 1

Woodson, Grattan C., Risk factors for osteoporosis in postmenopausal African–American women., Current Medical Research and Opinion, Volume 20, Number 10, 1 October 2004 , pp. 1681-1687(7)

Shergy W, Greenwald W, Woodson G, Chen P, Misurski D, Wagman R. Teriparatide Demonstrates Early Effects in Postmenopausal Women with Osteoporosis Abstract presentation at the American Association of Clinical Endocrinologist Meeting (April 28-May 2, 2004 Boston, Massachusetts) and the Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis Meeting (May 24-25, 2004 Bethesda, Maryland).

Michael R. McClung, M.D., E. Michael Lewiecki, M.D., Stanley B. Cohen, M.D., Michael A. Bolognese, M.D., Grattan C. Woodson, M.D. etal, Denosumab in Postmenopausal Women with Low Bone Mineral Density., N Engl J Med 2006;354:821-31

McClung, Michael R.; Lewiecki, E Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson, Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D.; Lederman, Samuel N.; Chesnut, Charles H.; Lain, Douglas; Kivitz, Alan J.; Holloway, Donna L.; Zhang, Charlie; Peterson, Mark C.; Bekker, Pirow J.; for the AMG 162 Bone Loss Study Group Denosumab in Postmenopausal Women With Low Bone Mineral Density. Gynecology Obstetrical & Gynecological Survey. 61(6):384-386, June 2006.

P. D. Miller, C. Christiansen, H. C. Hoeck, D.L Kindler; E. M. Lewiecki, G. Woodson, M. Ciesielska; A. A. Chines; G. Constantine; P. D. Delmas., Efficacy of Bazedoxifene for the Prevention of Postmenopausal Osteoporosis: Results of a 2-Year, Phase III, Placebo- and Active-Controlled Study JBMR 2007, Sup 1

P.D. Miller, A.A. Chines, C. Christiansen, H.C. Hoeck, D.L. Kendler, E.M. Lewiecki; G. C Woodson, A.B. Levine, G. Constantine; P.D. Delmas., Effects of Bazedoxifene on Bone Mineral Density and Turnover in Postmenopausal Women: 2-Year Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Study., J Bone Miner Res. 2008 Apr;23(4):525-35.

Grattan Woodson, M.D., Prospective; The Future of Primary Care — The Community Responds 2008 N Engl J Med 359;25

T.E. Dufresne, P.A. Chmielewski, J.H. Nurrea, B. Borah, X. Zhoua, R.J. Phipps, G. Woodson, P.D. Miller., Comparison of bone architecture via micro-ct after long-term treatment with risedronate and alendronate: A cross-sectional study in women with postmenopausal osteoporosis Bone; Volume 42, Supplement 1, Page S70 (March 2008)

JR Zanchetta, A. Høiseth, D.L. Kendler, C.K. Yuen, , P. Brown, S. Stonkus, S. Goemaere, C. Recknor, G. Woodson, M.A. Bolognese, E. Franek, M.L. Brandi, A. Wang, C. Libanati M. McClung, Denosumab Increased BMD of the Lumbar Spine, Total Hip, Femoral Neck, and Trochanter as Measured by QCT in Postmenopausal Women with Osteoporosis Journal of Clinical Densitometry Volume 13, Issue 1 , Page 108, January 2010

IR Reid, P Miller, JP Brown, D Kendler, A Fahrleitner-Pammer, I Valter, K Maasalu, M Bolognese, G Woodson, H Bone, B Ding, RB Wagman, J San Martin, MS Ominsky, DW Dempster on behalf of the Denosumab Phase 3 Bone Histology Study Group., Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies., J Bone Min Res 2010:25;2256-2265

D Dempster, H Zhou, R Recker, J Brown, M Bolognese, C Recknor, D Kendler, M Lewiecki, D Hanley, P Miller, G Woodson, R Linsay, N Binkley X Wan Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6-Month Results of a Randomized Controlled Trial Oral presentation at the 2011 Meeting of the American Society of Bone and Mineral Research.

M R. McClung, J R. Zanchetta, A Høiseth, D L. Kendler, C K Yuen, J P. Brown, S Stonkus, S Goemaere, C Recknor, G C. Woodson, M A. Bolognese, E Franek, M L Brandi, A Wang, C Libanati., Denosumab Densitometric Changes Assessed by QCT at the Hip and Spine in Postmenopausal Women With Osteoporosis 2012 Journal of Clinical Densitometry, 2012

# BOOKS

Woodson G C., *The Bird Flu Preparedness Planner.,* 15Nov2005 HCI Books, Deerfield, FL

Woodson G C., *The Bird Flu Manual.,* 15Sep2006, Booksurge Publishers, Charleston, SC

Woodson, G C., *The Coming Pandemic Catastrophe*, 15Aug2008, Booksurge Publishers, Charleston, SC